PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6 high uterine leiomyosarcoma to PD‐1 blockade
Clinical and Translational Medicine · 2024
DOI: 10.1002/ctm2.1655 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2024. Verfasst von Wout De Wispelaere und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Laboratory of Gynecological Oncology, University of Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Tumor Microenvironment, Leiomyosarcoma, Uterine Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kom op tegen Kanker, Stichting Tegen Kanker, Fonds Wetenschappelijk Onderzoek.
Abstract (Originalsprache)
Background
Uterine leiomyosarcomas (uLMS) are aggressive tumours with poor prognosis and limited treatment options. Although immune checkpoint blockade (ICB) has proven effective in some ‘challenging‐to‐treat’ cancers, clinical trials showed that uLMS do not respond to ICB. Emerging evidence suggests that aberrant PI3K/mTOR signalling can drive resistance to ICB. We therefore explored the relevance of the PI3K/mTOR pathway for ICB treatment in uLMS and explored pharmacological inhibition of this pathway to sensitise these tumours to ICB.
Methods
We performed an integrated multiomics analysis based on TCGA data to explore the correlation between PI3K/mTOR dysregulation and immune infiltration in 101 LMS. We assessed response to PI3K/mTOR inhibitors in immunodeficient and humanized uLMS patient‐derived xenografts (PDXs) by evaluating tumour microenvironment modulation using multiplex immunofluorescence. We explored response to single‐agent and a combination of PI3K/mTOR inhibitors with PD‐1 blockade in humanized uLMS PDXs. We mapped intratumoural dynamics using single‐cell RNA/TCR sequencing of serially collected biopsies.
Results
PI3K/mTOR over‐activation (pS6 high ) associated with lymphocyte depletion and wound healing immune landscapes in (u)LMS, suggesting it contributes to immune evasion. In contrast, PI3K/mTOR inhibition induced profound tumour microenvironment remodelling in an ICB‐resistant humanized uLMS PDX model, fostering adaptive anti‐tumour immune responses. Indeed, PI3K/mTOR inhibition induced macrophage repolarisation towards an anti‐tumourigenic phenotype and increased antigen presentation on dendritic and tumour cells, but also promoted infiltration of PD‐1+ T cells displaying an exhausted phenotype. When combined with anti‐PD‐1, PI3K/mTOR inhibition led to partial or complete tumour responses, whereas no response to single‐agent anti‐PD‐1 was observed. Combination therapy reinvigorated exhausted T cells and induced clonal hyper‐expansion of a cytotoxic CD8+ T‐cell population supported by a CD4+ T h 1 niche.
Conclusions
Our findings indicate that aberrant PI3K/mTOR pathway activation contributes to immune escape in uLMS and provides a rationale for combining PI3K/mTOR inhibition with ICB for the treatment of this patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Laboratory of Gynecological Oncology, University of Leuven, Leuven, Belgium.
- Department of Human Genetics, Laboratory for Translational Genetics, University of Leuven, Leuven, Belgium.
- Laboratory for Translational Genetics, Center for Cancer Biology (CCB), Flemish Institute of Biotechnology (VIB), Leuven, Belgium.
- Department of Gynecological Oncology, Antoni Van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Department of Medical Oncology, Laboratory of Medical and Molecular Oncology (LMMO), Vrije Universiteit Brussel - UZ Brussel, Brussels, Belgium.
- Department of Imaging and Pathology, Translational Cell and Tissue Research, University of Leuven, Leuven, Belgium.
ORCID-Profile: Daniela Annibali, Frédéric Amant
Förderung
- Kom op tegen Kanker
- Stichting Tegen Kanker
- Fonds Wetenschappelijk Onderzoek
- HORIZON EUROPE Marie Sklodowska-Curie Actions
Zitieren
APA
De Wispelaere, W., Annibali, D., Tuyaerts, S., Messiaen, J., Antoranz, A., Shankar, G., Dubroja, N., Herreros-Pomares, A., Baiden-Amissah, R. E. M., Orban, M. P., Delfini, M., Berardi, E., Van Brussel, T., Schepers, R., Philips, G., Boeckx, B., Baietti, M. F., Congedo, L., HoWangYin, K. Y., …, & Amant, F. (2024). PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6 high uterine leiomyosarcoma to PD‐1 blockade. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.1655
Vancouver
De Wispelaere W, Annibali D, Tuyaerts S, Messiaen J, Antoranz A, Shankar G, et al. PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6 high uterine leiomyosarcoma to PD‐1 blockade. Clinical and Translational Medicine. 2024. doi:10.1002/ctm2.1655
BibTeX
@article{DeWispelaere2024,
author = {De Wispelaere, Wout and Annibali, Daniela and Tuyaerts, Sandra and Messiaen, Julie and Antoranz, Asier and Shankar, Gautam and Dubroja, Nikolina and Herreros-Pomares, Alejandro and Baiden-Amissah, Regina E M and Orban, Marie-Pauline and Delfini, Marcello and Berardi, Emanuele and Van Brussel, Thomas and Schepers, Rogier and Philips, Gino and Boeckx, Bram and Baietti, Maria Francesca and Congedo, Luigi and HoWangYin, Kiave Yune and Bayon, Emilie and Van Rompuy, Anne-Sophie and Leucci, Eleonora and Tabruyn, Sebastien P and Bosisio, Francesca and Mazzone, Massimiliano and Lambrechts, Diether and Amant, Frédéric},
title = {PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6 high uterine leiomyosarcoma to PD‐1 blockade},
journal = {Clinical and Translational Medicine},
year = {2024},
doi = {10.1002/ctm2.1655}
}
EUVIMED